Get the Stockscreener App
7.32
0.27%
0.02
Amneal Pharmaceuticals Inc stock is traded at $7.32, with a volume of 1.42M.
It is up +0.27% in the last 24 hours and down -5.55% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$7.30
Open:
$7.3
24h Volume:
1.42M
Relative Volume:
0.74
Market Cap:
$2.29B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-10.76
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+2.23%
1M Performance:
-5.55%
6M Performance:
-11.49%
1Y Performance:
+7.96%
1-Day Range:
$7.19
$7.385
1-Week Range:
$7.19
$7.385
52-Week Range:
$6.29
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
7.32 | 2.24B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal to Participate at Upcoming Investor Conferences in June - GlobeNewswire
Amneal CEO and CFO Set for Exclusive Presentations at Two Major Healthcare Investor Conferences - Stock Titan
Bank of America Corp DE Has $4.41 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
FDA approves Amneal’s DHE migraine/cluster headache autoinjector - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $716,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Pharyngitis Treatment Market with Antibiotics and Home - openPR.com
3 Reasons Growth Investors Will Love Amneal (AMRX) - Yahoo Finance
Deutsche Bank AG Has $1.06 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Hydroxychloroquine Market to Witness Remarkable Growth with - openPR.com
Insider Sell: Nikita Shah Sells Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight - PR Newswire
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by BNP Paribas Financial Markets - Defense World
Ameriprise Financial Inc. Sells 49,121 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal gets U.S. FDA nod for Brekiya as a migraine treatment - MSN
US FDA approves Amneal's self-administered migraine treatment - Reuters
AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress - Yahoo Finance
Amneal Gets FDA Nod For Self-Administrable Migraine Injection - MSN
The Manufacturers Life Insurance Company Has $689,000 Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal gets FDA approval for Brekiya to treat migraine and cluster headaches - World Pharmaceutical Frontiers
Amneal’s Brekiya autoinjector approved by FDA for migraines - Investing.com Nigeria
Northern Trust Corp Purchases 156,699 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal’s Brekiya autoinjector approved by FDA for migraines By Investing.com - Investing.com South Africa
Amneal Gets FDA Nod For Self-Administrable Migraine Injection By Stocktwits - Investing.com India
FDA Approves Amneal's (AMRX) Brekiya Autoinjector for Migraine R - GuruFocus
US FDA approves Amneal’s self-administered migraine treatment - 1470 & 100.3 WMBD
FDA Greenlights Amneal's (AMRX) Innovative Migraine Treatment | AMRX Stock News - GuruFocus
Amneal Pharmaceuticals' Brekiya Approved by FDA - marketscreener.com
Amneal rises after US FDA greenlights self-administered migraine treatment - TradingView
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults - The Manila Times
US FDA approves Amneal's migraine treatment - marketscreener.com
Amneal Receives U.S. FDA Approval for Brekiya® - GlobeNewswire
Breakthrough: First At-Home Injectable Migraine Treatment Gets FDA Green LightWhat Makes It Different - Stock Titan
This Insider Has Just Sold Shares In Amneal Pharmaceuticals - simplywall.st
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Lowered by StockNews.com - Defense World
Director John Kiely Sells 50,000 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing - insights.citeline.com
Key Trends Shaping the Future of Filgrastim Biosimilars Market: Amneal Pharmaceuticals' Fylnetra Marks A Ne... - WhaTech
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock? - MSN
Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease - Business Wire
Amneal Pharmaceuticals to add 200 jobs at its Brookhaven factory - Newsday
Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect? - Yahoo Finance
Amneal and Apiject join forces to boost US pharmaceutical manufacturing - World Pharmaceutical Frontiers
Decoding Amneal Pharmaceuticals Inc (AMRX): A Strategic SWOT Ins - GuruFocus
Amneal Pharmaceuticals Approves Key Proposals at Annual Meeting - TipRanks
Here is Why Growth Investors Should Buy Amneal (AMRX) Now - Yahoo Finance
Are Options Traders Betting On A Big Move In Amneal Pharmaceuticals Stock? - Barchart.com
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal - GlobeNewswire
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced ... - Bluefield Daily Telegraph
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
18.36%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):